BIOHARVEST SCIENCES INC. Annual Report - How They Did This Year

I’m writing this guide to help you understand how BioHarvest Sciences performed recently. We will skip the dense legal filings and break down the key points so you can decide if this company fits your investment goals.

1. What does this company do?

BioHarvest is a biotech innovator that "brews" high-quality, plant-based ingredients in controlled tanks instead of using traditional farms. Think of it like a craft brewery, but for health supplements. This process creates consistent, pure nutrients without pesticides. They make money in two ways: selling their own branded health products (like VINIA®, a red grape cell supplement) and acting as a "factory for hire" for other companies. Their manufacturing facility in Rehovot, Israel, is the hub for this production.

2. Major wins and changes

The company is in a heavy growth phase:

• Market Move: They joined the NASDAQ (ticker: BHST) in November 2024. This move puts them on a global stage to attract more investors.
• Scientific Validation: Recent clinical trials showed that VINIA® significantly improved insulin sensitivity and reduced HbA1c levels in patients with Type 2 diabetes. These results help them transition from a general wellness brand to a clinically backed health solution.
• Intellectual Property: They hold 23 patents covering their "brewing" technology. This creates a "moat" that prevents competitors from copying their proprietary process.

3. Financial health: The "Growth" Reality

BioHarvest is growing its sales, but they still spend more than they earn to fund marketing and expansion.

• Revenue Growth: The company is heading in the right direction. They reported $34.5 million in revenue for 2025, a 36.9% increase over the $25.2 million earned in 2024.
• The Bottom Line: Despite rising sales, they are still losing money. They reported an $11.1 million loss for 2025, largely due to research costs and the expenses of joining the NASDAQ.
• Cash Flow: Auditors have noted "substantial doubt" about the company’s ability to keep operating without raising more money. With only $8.2 million in cash at the end of 2025, they will likely need to borrow money or issue more shares, which reduces your ownership percentage.

4. Key risks

• Geopolitical Instability: Their primary facilities and most staff are in Israel. Ongoing regional conflicts pose a real threat. Any escalation could cause labor shortages, facility damage, or export restrictions that would halt their supply chain.
• Cash Flow: They are currently losing money. If they cannot secure more funding or reach a profit, they may need to issue more shares or scale back growth, which would hurt their competitive edge.
• Regulatory Hurdles: They rely on FDA safety designations. Any legal challenges to their health claims or changes in supplement regulations could force them to rebrand or pull products from the U.S. market.

5. Future outlook

The company is betting everything on its ability to scale. Success depends on turning their ingredients into a steady, profitable income stream by landing high-volume partners and launching new products. They are growing sales, but the big question is whether they can reach a profit before they run out of cash.

Investor Takeaway: BioHarvest is a classic "high-risk, high-reward" play. They have a unique, patented technology and growing sales, but their current cash position and the geopolitical risks in Israel mean they are under significant pressure to reach profitability quickly. If you are considering an investment, keep a close eye on their quarterly cash burn and any announcements regarding new manufacturing partnerships.